Latest Administration News

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Anagenics reports a marked reduction in operating cash outflow and expenses following a strategic restructuring, setting the stage for improved financial stability in the coming quarter.

JPMorgan Asset Management has announced estimated cash distributions for its Global Equity Premium Income ETFs for February 2025, alongside a detailed timetable for investors to follow.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Yowie Group Ltd has called in its loan facility with Keybridge Capital Limited following Keybridge's appointment of a Voluntary Administrator, prompting Yowie to explore new capital solutions amid recovery uncertainties.

WAM Global reports a robust 23.7% increase in its investment portfolio for the year ending December 2024, prompting a rise in fully franked dividends including a special payout. The company’s strong financial results underscore its confidence in sustained growth and shareholder returns.

Wellnex Life Limited has announced a non-renounceable entitlement offer to raise approximately $22.1 million at $0.65 per share, supporting its planned AIM listing and strategic growth initiatives.

Keybridge Capital Limited has appointed a voluntary administrator following a series of legal setbacks and an inability to raise crucial capital, leading to the suspension of its shares.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Smartgroup has been appointed as the exclusive provider of salary packaging and novated leasing services for Monash Health’s 25,000 employees under a new multi-year contract starting April 2025.

Gladiator Resources Limited reported a $703,000 net cash outflow for the December 2024 quarter, driven by exploration and evaluation expenses, yet maintains sufficient capital to fund operations into 2025.